Stéphane Honoré to Antiviral Agents
This is a "connection" page, showing publications Stéphane Honoré has written about Antiviral Agents.
Connection Strength
0.212
-
Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Microb Drug Resist. 2021 Mar; 27(3):281-290.
Score: 0.086
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. Int J Antimicrob Agents. 2021 Jan; 57(1):106243.
Score: 0.021
-
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients. Int J Antimicrob Agents. 2021 Jan; 57(1):106236.
Score: 0.021
-
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. Int J Antimicrob Agents. 2021 01; 57(1):106241.
Score: 0.021
-
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. Int J Antimicrob Agents. 2021 Jan; 57(1):106242.
Score: 0.021
-
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 Jul - Aug; 36:101791.
Score: 0.021
-
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020 May - Jun; 35:101738.
Score: 0.020